Analysis of lung cancer cases diagnosed in an Internal Medicine Department: From January 2001 to September 2006;Análisis de los casos de cáncer de pulmón diagnosticados en el Servicio de Medicina Interna del Hospital de Navarra: Enero de 2001 a septiembre de 2006

Anales del Sistema Sanitario de Navarra

Volumn 30, Issue 3, 2007, Pages 353-362

  Fernández Ladrón, Valentina ^a   Alonso, J L ^a   Munuera, L ^a   Moya, J L ^a   Lasa, B ^a   Suarez A ^a   Gutierrez J ^a  

^a Universidad Pública de Navarra   (Spain)

Author keywords

Lung cancer; Survival time

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER STAGING; FEMALE; GENDER; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; SMOKING HABIT; SURVIVAL TIME; SYMPTOMATOLOGY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BRONCHOSCOPY; CARCINOMA, NON-SMALL-CELL LUNG; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOGRAPHY, THORACIC; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SMOKING; SURVIVAL ANALYSIS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 38349141537     PISSN: 11376627     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. TRAVIS WD, LUBIN J, RIAS L, DEVESA S. United States lung cancer incidence trends. Cáncer 1996; 77: 2464-2470.
2. AHSAN H, THOMAS DC. Medical biology: on the etiology of lung cancer. J Am Med Assoc 2004; 292: 2026.
3. GÓMEZ C, DE CASTRO J, GONZÁLEZ M. Factores etiológicos del cáncer de pulmón: fumador activo, fumador pasivo, carcinógenos medioambientales y factores genéticos. Med Clin (Barc) 2007; 128: 390-396.
4. FERLAY J, BRAY F, PISAN P, PARKING D. GLOBOCAN 2002: Cancer Incidence, Mortality and prevalence WorldWide. Lyon, France: IARC Press; 2004.
5. LÓPEZ ABENTE G, POLLÁN M, ARAGONÉS N, PÉREZ B, HERNÁNDEZ V, LOPE V, SUÁREZ B. Situación del cáncer en españa: incidencia. An Sist Sanit Navar 2004; 27: 165-173.
6. HERBST RS, BAJORIN DF, BLEIBERG H, BLUM DM, HAO D, JOHNSON BE et al. American Society of Clinical Oncology. Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening. J Clin Oncol 2006; 24: 190-205.
7. WINGO PA, CARDINEZ CJ, LANDIS SH, GREENLEE RT, RIES LA, ANDERSON RN et al. Long-term trends in cancer mortality in the United States. Cancer 2003; 97: 3133-3275.
8. OZOLS RF, HERBST RS, COLSON YL, GRALOW J, BONNER J, CURRAN WJ et al. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening. J Clin Oncol 2007; 25: 146-162.
9. MORENO C, FLORISTÁN Y, EGÜÉ S N. Tendencias recientes de las principales causas de muerte en Navarra. 1995-2004. An Sist Sanit Navar 2006: 29; 399-414.
10. ARDANAZ E, MORENO C, PÉREZ DE RADA ME, ESPONJA C, NAVARIDAS N. Incidencia de cáncer en Navarra (1998-2000). An Sist Sanit Navar 2004; 27: 373-380.
11. ABAL J, BLANCO MA, GARCÍA DE LA INFANTA R, PÉREZ C, GONZÁLEZ L, LAMELA J. Coste hospitalario del diagnóstico del cáncer de pulmón. Arch Bronconeumol 2006;42: 569-574.
12. BECKLES MA, SPIRO SG, COLICE GL, RUDD RM. Initial evaluation of the patients with lung cancer: symptoms, signs, laboratory test, and paraneoplasic syndromes. Chest 2003; 123: 97-104.
13. FORGA L. ANDA E. MARTÍNEZ DE ESTEBAN JP. Síndromes hormonales paraneoplásicos. An Sist Sanit Navar 2005; 28: 213-226.
14. ADERKA D, BROWN A, ZELIKOVSKI A, PINKHAS J. Idiopathic deep thrombosis in a apparently healthy patients as a premonitory sing of occult cancer. Cancer 1986; 57: 1846-1849.
15. GARCÍA M, ALONSO M, GONZÁLEZ MJ, MALO E, FERNÁNDEZ MC, ORTEGA JM et al. Trombosis venosa y cáncer oculto. Angiología 2001; 53: 301-309.
16. BACH PB, JETT JR, PASTORINO U, TOCKMAN MS, SWENSEN SJ, BEGG CB. Computed Tomography Screening and lung cancer outcomes. JAMA 2007; 297: 953-961.
17. ZABALA DC. Diagnostic fiberoptic bronchoscopy: Techniques and results of biopsy in 600 patients. Chest 1975; 68: 12-19.
18. PAVLOV RM, MIKHAILOV LG, VIASOV VI. Advantages and disvadvantages of fibrobronchoscopy and rigid bronchoscopy in the diagnosis of lung tumors. Probl Turber 1986; 11: 45-46.
19. SÁNCHEZ DE COS J, MIRAVET L, ABAL J, NUÑEZ A, HERNÁNDEZ J, CASTAÑAR AM et al. Estudio multicéntrico epidemiológico-clínico de cáncer de pulmón en España (estudio EpicliCP-2003). Arch Bronconeumol 2006; 42: 446-452.
20. FERNÁNDEZ E, BORRÁS JM, LEVIO F, SCHIAFFINO A, GARCÍA M, LA VECCCHIA C. Mortalidad por cáncer en España, 1955-1994. Med Clin (Barc) 2000; 114: 449-451.
21. CORRAL J, DISDIER C, SOJO A, SÁNCHEZ DE COS J, MASA JF, RIESCO JA. Supervivencia global a largo plazo en el cáncer de pulmón. Análisis de una serie de 610 pacientes no seleccionados. Arch Bronconeumol 2004; 40: 268-274.
22. International Early Lung Cancer Action Program Investigators. Survival of patients with stage I lung cancer detected on CT screening. N Eng J Med 2006; 355: 1763-1771.
23. VIÑES JJ. La efectividad de la detección precoz de las enfermedades. An Sist Sanit Navar 2007; 30: 11-27.
24. MIDTHUN DE. Lung Cancer Screening Results: Easily Misunderstood. Mayo Clin Proc 2007; 82: 14-15.